Dana-Farber Cancer Institute boasts an impressive history of key discoveries about the immune system. Their powerhouse investigators have been on the frontlines. Dana-Farber’s research revealed that a protein known as PD-L1 is expressed on normal and cancer cells, enabling cancers to evade the immune response, and that blocking PD-L1 and a related protein, PD-1, could unleash the immune attack on tumor cells. PICI scientists at Dana-Farber are leaders in immunology and contribute greatly to our research agenda. Laurie H. Glimcher, MD | Director All Investigators Related Press Release PICI, JDRF and Helmsley Trust Form Research Initiative Cancer Research Heroes, Research Update Personalized Cancer Vaccines to Conquer Cancer Research Update Personalized cancer neoantigen vaccines show success in two small studies Partner Highlight Seeking Solutions for Deadly Brain Tumors: ACGT Our Impact, Research Update Tackling Pancreatic Cancer with a Triple Threat Our Impact Highlights of 2020: PICI’s Progress Research Project Brain Tumor Program Point of View How to Engage Your Employees During a Pandemic Our Impact, Patient Story A Legacy of Service and a New Day for Pancreatic Cancer